Accession Number:

ADA379590

Title:

Evaluation of Drug and Vaccine Candidates in the Human Malaria/Aotus Monkey Model

Descriptive Note:

Annual rept. 1 Mar 1999-28 Feb 2000

Corporate Author:

PROMED TRADING S A MIAMI FL

Personal Author(s):

Report Date:

2000-03-01

Pagination or Media Count:

37.0

Abstract:

A C2A clone of a Mefloquine resistant Plasmodium faiciparum strain was successfully adapted to splenectomized and intact Aotus. Chioroquine resistance reversal was achieved in 33 Aotus infected with the AMRU-1 strain of Plasmodium vivax by using chloroquine at 1Omgkg and prochiorperazine at 20 mgkg in combination. Artelinic Acid WR255663AKBM041 31 when given orally at 2 mgkg x three days suppressed infections of the AMRU-1 CQR but cleared SAL-1 strains of P. vivax in Aotus monkeys. Artelinic Acid WR255663AKBM04131 administered orally at 2-24 mgkg x three days was effective against infections of P. falciparum FVO strain in Aotus monkeys. Orally or intravenously administered falcipain APC33l 7 was ineffective against infections of P. falciparum FVO. Artelinic Acid and Artesunate were effective against infections with P. falciparum FVO in Aotus monkeys. Passive transfer of anti-EBA-175 Region II protein monoclonal antibodies was not effective at controlling parasitemia in Aotus monkeys infected with P. falciparum. Immunization with a plasmid encoding region ll of EBA-1 75 followed with by a EBA-175 recombinant protein boost partially protected Aotus monkeys against P. falciparum malaria. Topical ocular administration of a plasmid DNA vaccine encoding an AMA-1 P. falciparum blood stage antigen did not induce an immune response in Aotus monkeys.

Subject Categories:

  • Medicine and Medical Research
  • Microbiology

Distribution Statement:

APPROVED FOR PUBLIC RELEASE